Efficacy of combination therapy of interferon-α with ursodeoxycholic acid in chronic hepatitis C: A randomized controlled clinical trial

[1]  Koichi Kanai,et al.  HCV genotypes in chronic hepatitis C and response to interferon , 1992, The Lancet.

[2]  Motohiro Shibata,et al.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon‐α therapy: Relationship to genotypes of hepatitis C virus , 1992, Hepatology.

[3]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[4]  E. Schiff,et al.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. , 1989, The New England journal of medicine.

[5]  O. Weiland,et al.  High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon‐α2b for 60 weeks , 1994, Hepatology.

[6]  Eugene R. Schiff,et al.  Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa , 1989 .

[7]  A. Roda,et al.  Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose‐response study , 1991, Hepatology.

[8]  A. Moreno,et al.  High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. , 1991, Hepatology.

[9]  N. Hayashi,et al.  Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. , 1993, Gastroenterology.

[10]  A. Moreno,et al.  High doses of recombinant α‐interferon or γ‐interferon for chronic hepatitis C: A randomized, controlled trial , 1991 .

[11]  K. Chayama,et al.  Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.

[12]  H. Okamoto,et al.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. , 1992, The Journal of general virology.

[13]  S. Banks,et al.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1989, The New England journal of medicine.

[14]  O. Yokosuka,et al.  Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: Increase of the virus in advanced liver disease , 1993, Hepatology.

[15]  P. Couzigou,et al.  Recombinant human α‐interferon in patients with chronic non‐A, non‐B hepatitis: A multicenter randomized controlled trial from France , 1991 .

[16]  R. Franceschini,et al.  Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis , 1991, European Journal of Clinical Pharmacology.

[17]  A. Kasahara,et al.  Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. , 1993 .

[18]  R. Tedder,et al.  Detection of hepatitis C viral sequences in blood donations by "nested" polymerase chain reaction and prediction of infectivity , 1990, The Lancet.

[19]  K. Chayama,et al.  Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction , 1993 .

[20]  Y. Matsuzawa,et al.  Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum γ-glutamyltranspeptidase levels , 1996, Journal of Gastroenterology.